Fulcrum Therapeutics Reports Positive Phase 1b Results for Pociredir in Sickle Cell Disease

Reuters06:30

<a href="https://laohu8.com/S/FULC">Fulcrum Therapeutics</a> Reports Positive Phase 1b Results for Pociredir in Sickle Cell Disease

Fulcrum Therapeutics Inc. announced positive initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial evaluating pociredir in patients with sickle cell disease. The interim analysis showed a dose-response relationship, with a mean absolute increase in fetal hemoglobin (HbF) of 9.9% at Week 6 in the 20 mg cohort, compared to 5.6% in the 12 mg cohort. At Week 6, 58% of patients in the 20 mg cohort achieved absolute HbF levels of 20% or higher. Among patients who reached the Week 12 visit, the 20 mg cohort demonstrated a greater than 3.75-fold mean induction of HbF. Pociredir was generally well-tolerated with no treatment-related serious adverse events reported. These results were presented at the 67th American Society of Hematology Annual Meeting, and Fulcrum Therapeutics will host an investor event on December 7, 2025, to further discuss the data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598069-en) on December 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589822050?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-07 06:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589822050","market":"nz","top_or_hot":-1,"title":"Fulcrum Therapeutics Reports Positive Phase 1b Results for Pociredir in Sickle Cell Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> Reports Positive Phase 1b Results for Pociredir in Sickle Cell Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced positive initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial evaluating pociredir in patients with sickle cell disease. The interim analysis showed a dose-response relationship, with a mean absolute increase in fetal hemoglobin (HbF) of 9.9% at Week 6 in the 20 mg cohort, compared to 5.6% in the 12 mg cohort. At Week 6, 58% of patients in the 20 mg cohort achieved absolute HbF levels of 20% or higher. Among patients who reached the Week 12 visit, the 20 mg cohort demonstrated a greater than 3.75-fold mean induction of HbF. Pociredir was generally well-tolerated with no treatment-related serious adverse events reported. These results were presented at the 67th American Society of Hematology Annual Meeting, and Fulcrum Therapeutics will host an investor event on December 7, 2025, to further discuss the data.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598069-en) on December 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fulcrum Therapeutics Reports Positive Phase 1b Results for Pociredir in Sickle Cell Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFulcrum Therapeutics Reports Positive Phase 1b Results for Pociredir in Sickle Cell Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-07 06:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> Reports Positive Phase 1b Results for Pociredir in Sickle Cell Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced positive initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial evaluating pociredir in patients with sickle cell disease. The interim analysis showed a dose-response relationship, with a mean absolute increase in fetal hemoglobin (HbF) of 9.9% at Week 6 in the 20 mg cohort, compared to 5.6% in the 12 mg cohort. At Week 6, 58% of patients in the 20 mg cohort achieved absolute HbF levels of 20% or higher. Among patients who reached the Week 12 visit, the 20 mg cohort demonstrated a greater than 3.75-fold mean induction of HbF. Pociredir was generally well-tolerated with no treatment-related serious adverse events reported. These results were presented at the 67th American Society of Hematology Annual Meeting, and Fulcrum Therapeutics will host an investor event on December 7, 2025, to further discuss the data.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598069-en) on December 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL2QZZPZ:1","article_id":"2589822050","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589822050","pubTimestamp":1765060216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Fulcrum Therapeutics Inc. announced positive initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial evaluating pociredir in patients with sickle cell disease. The interim analysis showed a dose-response relationship, with a mean absolute increase in fetal hemoglobin  of 9.9% at Week 6 in the 20 mg cohort, compared to 5.6% in the 12 mg cohort. At Week 6, 58% of patients in the 20 mg cohort achieved absolute HbF levels of 20% or higher. Among patients who reached the Week 12 visit, the 20 mg cohort demonstrated a greater than 3.75-fold mean induction of HbF. Pociredir was generally well-tolerated with no treatment-related serious adverse events reported. These results were presented at the 67th American Society of Hematology Annual Meeting, and Fulcrum Therapeutics will host an investor event on December 7, 2025, to further discuss the data.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4007":"制药","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","FULC":"Fulcrum Therapeutics","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Fulcrum Therapeutics报告Pociredir治疗镰状细胞病的1b期结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"FULC":0.9},"content_text":"Fulcrum Therapeutics Reports Positive Phase 1b Results for Pociredir in Sickle Cell Disease\n    \n\n        Fulcrum Therapeutics Inc. announced positive initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial evaluating pociredir in patients with sickle cell disease. The interim analysis showed a dose-response relationship, with a mean absolute increase in fetal hemoglobin (HbF) of 9.9% at Week 6 in the 20 mg cohort, compared to 5.6% in the 12 mg cohort. At Week 6, 58% of patients in the 20 mg cohort achieved absolute HbF levels of 20% or higher. Among patients who reached the Week 12 visit, the 20 mg cohort demonstrated a greater than 3.75-fold mean induction of HbF. Pociredir was generally well-tolerated with no treatment-related serious adverse events reported. These results were presented at the 67th American Society of Hematology Annual Meeting, and Fulcrum Therapeutics will host an investor event on December 7, 2025, to further discuss the data.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598069-en) on December 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589822050","isCrawlerRequest":true}